Merrimack Pharmaceuticals, Inc operates as a clinical stage biopharmaceutical company that targets biomarker-defined cancers. The company is developing MM-310, an antibody-directed nanotherapeutic, which is in Phase I clinical trial to treat patients with solid tumors. Its preclinical product candidates include MM-401, an agonistic antibody targeting a novel immuno-oncology target; and MM-201, a stabilized agonist-Fc fusion protein targeting death receptors 4 and 5.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Phone617-441-1000
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$144.27 million
Profitability
Miscellaneous
Employees27
Next Earnings Date11/6/2019 (Estimated)
OptionableOptionable
Merrimack Pharmaceuticals (NASDAQ:MACK) Frequently Asked Questions
What is Merrimack Pharmaceuticals' stock symbol?
Merrimack Pharmaceuticals trades on the NASDAQ under the ticker symbol "MACK."
How often does Merrimack Pharmaceuticals pay dividends? What is the dividend yield for Merrimack Pharmaceuticals?
Merrimack Pharmaceuticals announced a dividend on Thursday, July 25th. Shareholders of record on Wednesday, August 28th will be paid a dividend of $1.4967 per share on Thursday, September 5th. The ex-dividend date of this dividend is Friday, September 6th. View Merrimack Pharmaceuticals' Dividend History.
When did Merrimack Pharmaceuticals' stock split? How did Merrimack Pharmaceuticals' stock split work?
Merrimack Pharmaceuticals shares reverse split on the morning of Wednesday, September 6th 2017. The 1-10 reverse split was announced on Thursday, August 31st 2017. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, September 5th 2017. An investor that had 100 shares of Merrimack Pharmaceuticals stock prior to the reverse split would have 10 shares after the split.
How were Merrimack Pharmaceuticals' earnings last quarter?
Merrimack Pharmaceuticals Inc (NASDAQ:MACK) released its earnings results on Friday, May, 10th. The biopharmaceutical company reported ($0.78) earnings per share for the quarter, beating the consensus estimate of ($0.92) by $0.14. View Merrimack Pharmaceuticals' Earnings History.
When is Merrimack Pharmaceuticals' next earnings date?
What price target have analysts set for MACK?
1 equities research analysts have issued 1-year price targets for Merrimack Pharmaceuticals' stock. Their forecasts range from $10,000,000.00 to $0.00. On average, they expect Merrimack Pharmaceuticals' stock price to reach $0.00 in the next twelve months. This suggests that the stock has a possible downside of 100.0%. View Analyst Price Targets for Merrimack Pharmaceuticals.
What is the consensus analysts' recommendation for Merrimack Pharmaceuticals?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Merrimack Pharmaceuticals in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Merrimack Pharmaceuticals.
Has Merrimack Pharmaceuticals been receiving favorable news coverage?
Media coverage about MACK stock has been trending somewhat positive recently, according to InfoTrie Sentiment. The research firm rates the sentiment of news coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Merrimack Pharmaceuticals earned a news impact score of 0.8 on InfoTrie's scale. They also gave news headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the company's share price in the next several days. View News Stories for Merrimack Pharmaceuticals.
Are investors shorting Merrimack Pharmaceuticals?
Merrimack Pharmaceuticals saw a decrease in short interest in the month of September. As of September 30th, there was short interest totalling 585,200 shares, a decrease of 5.4% from the August 30th total of 618,500 shares. Based on an average daily volume of 72,500 shares, the days-to-cover ratio is presently 8.1 days. Currently, 4.5% of the company's stock are short sold. View Merrimack Pharmaceuticals' Current Options Chain.
Who are some of Merrimack Pharmaceuticals' key competitors?
Some companies that are related to Merrimack Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Alexion Pharmaceuticals (ALXN), Incyte (INCY), Seattle Genetics (SGEN), EXACT Sciences (EXAS), BioMarin Pharmaceutical (BMRN), Array Biopharma (ARRY), Alnylam Pharmaceuticals (ALNY), Neurocrine Biosciences (NBIX) and Ionis Pharmaceuticals (IONS).
What other stocks do shareholders of Merrimack Pharmaceuticals own?
Who are Merrimack Pharmaceuticals' key executives?
Merrimack Pharmaceuticals' management team includes the folowing people:
- Dr. Richard Peters, Pres, CEO & Director (Age 56)
- Ms. Jean M. Franchi, CFO & Treasurer (Age 53)
- Mr. Jeffrey A. Munsie, Gen. Counsel, Head of Corp. Operations & Sec. (Age 42)
- Dr. Daryl C. Drummond Ph.D., Head of Research (Age 50)
- Dr. Sergio L. Santillana, Chief Medical Officer (Age 56)
Who are Merrimack Pharmaceuticals' major shareholders?
Merrimack Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Campbell & CO Investment Adviser LLC (0.18%). Company insiders that own Merrimack Pharmaceuticals stock include Fund Lp 22Nw, Jason Aryeh, Jfl Capital Management, Llc and Lp 22Nw. View Institutional Ownership Trends for Merrimack Pharmaceuticals.
Which institutional investors are buying Merrimack Pharmaceuticals stock?
MACK stock was purchased by a variety of institutional investors in the last quarter, including Campbell & CO Investment Adviser LLC. Company insiders that have bought Merrimack Pharmaceuticals stock in the last two years include Fund Lp 22Nw, Jason Aryeh, Jfl Capital Management, Llc and Lp 22Nw. View Insider Buying and Selling for Merrimack Pharmaceuticals.
How do I buy shares of Merrimack Pharmaceuticals?
Shares of MACK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Merrimack Pharmaceuticals' stock price today?
One share of MACK stock can currently be purchased for approximately $4.11.
How big of a company is Merrimack Pharmaceuticals?
What is Merrimack Pharmaceuticals' official website?
How can I contact Merrimack Pharmaceuticals?
Merrimack Pharmaceuticals' mailing address is ONE KENDALL SQUARE SUITE B7201, CAMBRIDGE MA, 02139. The biopharmaceutical company can be reached via phone at 617-441-1000 or via email at [email protected]
MarketBeat Community Rating for Merrimack Pharmaceuticals (NASDAQ MACK)
MarketBeat's community ratings are surveys of what our community members think about Merrimack Pharmaceuticals and other stocks. Vote "Outperform" if you believe MACK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MACK will underperform the S&P 500 over the long term. You may vote once every thirty days.
